|
Iovance Biotherapeutics inc (NASDAQ: IOVA) |
|
Iovance Biotherapeutics inc
IOVA's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Iovance Biotherapeutics Inc growth rates, revenue grew
by 6798.46 % in the first quarter of 2025 from the same quarter a year ago.
Ranking at No. 14
Biotechnology & Pharmaceuticals industry recorded
growth of revenues by 12.76 %
Iovance Biotherapeutics Inc net loss increased from $-113 millions, to $-116 millions in first quarter of 2025,
• More on IOVA's Growth
|
|
Iovance Biotherapeutics Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 17.6 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 3.1.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.2.
• More on IOVA's Valuation
|
|
|
|
|
Iovance Biotherapeutics Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 17.6 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 3.1.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.2.
Iovance Biotherapeutics Inc Price to Book Ratio is at 0.86 lower than Industry Avg. of 1880.07. and higher than S&P 500 Avg. of 0.01
• More on IOVA's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com